论文部分内容阅读
目的:探讨玻璃粘连蛋白血清学表达与乳腺癌早期诊断的相关性。方法:采用酶联免疫吸附试验(ELISA)定量测定62例乳腺癌(0-Ⅰ期癌22例,Ⅱ-Ⅲ期癌40例)和8例乳腺良性病变患者血清玻璃粘连蛋白水平,分析玻璃粘连蛋白表达在良性与各期乳腺癌中的变化规律,同时比较CA153、CA125、CEA的表达情况。结果:0-Ⅰ期乳腺癌组血清玻璃粘连蛋白的表达水平(231.45±30.54μg/m L)显著高于良性对照组(197.84±24.31μg/m L)和Ⅱ-Ⅲ期乳腺癌组(209.34±31.25μg/m L),差异均有统计学意义(P<0.01);玻璃粘连蛋白血清表达水平与乳腺癌组织学分级、年龄、肿瘤大小、月经状况、ER、PR、Her-2及Ki-67表达无关(P>0.05);而血清CA153、CA125、CEA表达水平随着临床分期升高而升高,其中CA153的表达存在统计学差异(P<0.05)。结论:血清玻璃粘连蛋白水平在早期阶段乳腺癌(0-Ⅰ期)显著高于良性和中期(Ⅱ-Ⅲ期)乳腺癌患者,提示玻璃粘连蛋白可能是一项有潜力的乳腺癌早期诊断指标,而血清CA153、CA125、CEA表达则主要与乳腺癌病情发展相关。
Objective: To investigate the correlation between the expression of vitronectin and the early diagnosis of breast cancer. Methods: Serum vitronectin level was determined by enzyme-linked immunosorbent assay (ELISA) in 62 cases of breast cancer (22 cases of stage 0-I and 40 cases of stage II-III) and 8 cases of benign breast lesions. Protein expression in benign and various stages of breast cancer changes, while CA153, CA125, CEA expression. Results: Serum vitronectin level in stage 0-Ⅰ breast cancer was significantly higher than that in benign control (197.84 ± 24.31μg / m L) and group Ⅱ-Ⅲ (209.34 ± 23.54μg / m L) ± 31.25μg / m L), the differences were statistically significant (P <0.01); The expression of vitreousin in serum was correlated with histological grade, age, tumor size, menstrual status, ER, PR, Her- -67 expression (P> 0.05). However, the expression of CA153, CA125 and CEA increased with the increase of clinical stage, and the expression of CA153 was statistically different (P <0.05). Conclusions: The serum level of vitronectin is significantly higher in early stages of breast cancer (stage 0-Ⅰ) than in benign and mid stage (stage Ⅱ-Ⅲ) breast cancers, suggesting that vitronectin may be a potential indicator of early diagnosis of breast cancer , While the serum CA153, CA125, CEA expression is mainly associated with the development of breast cancer.